GlobeNewsWire
30 Jun 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Dogwood Therapeutics expects to release Phase 2b data for its lead candidate, Halneuron, in the fall of 2026. — Phase 2b results are primary catalysts for biotech valuations as they provide the first significant evidence of efficacy and safety in a target population.
+0.60The FDA has cleared Dogwood's SP16 candidate to progress into Phase 1b development for chemotherapy-induced peripheral neuropathy. — Regulatory clearance to advance a pipeline asset reduces clinical risk and marks a tangible step toward commercialization.
+0.40The National Cancer Institute is fully funding the forthcoming SP16 IV Phase 1b trial. — Non-dilutive funding from a prestigious government body validates the science and preserves the company's cash runway.
+0.30Continue reading
6 related stories
Search tags
Dogwood has appointed Dr. Iain Dukes, a partner at OrbiMed and former Merck/Amgen executive, as Chair of its new Scientific Advisory Board. — Adding high-profile industry leadership and an OrbiMed connection enhances corporate governance and potential strategic partnership visibility.
+0.20Which stocks this story touches
The company appointed a highly experienced biopharma executive as Chair of its new Scientific Advisory Board and provided positive updates on clinical pipeline progress.
Mentioned only as the parent entity of the company's largest shareholder without any material news affecting its value.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
